Reducing immune tolerance induced by PD-L1
US10619136B2 · kind B2 · utility
1Cited by
9References
27Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 8, 2016 |
| Grant date | Apr 14, 2020 |
| Priority date | — |
| Expiry date | Jan 4, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compositions and methods for reducing immune tolerance associated with CAR T cell therapy. Embodiments of the present disclosure include isolated nucleic acid sequence comprising a nucleic acid sequence that encodes modified programmed cell death protein 1 (PD-1) and a nucleic acid sequence that encodes chimeric antigen receptor (CAR).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.